Dr. Trideva Sastri Koduru is a faculty member in pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA–based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR’s Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri’s research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.

• ForewordPrefaceAcknowledgmentsAbout the AuthorChapter 1 Introduction to Neurodegenerative DisordersChapter 2 Traditional Therapies for Neurodegenerative DiseasesChapter 3 Nucleic Acid Therapies for Neurodegenerative DisordersChapter 4 Antisense and RNA–Interference Strategies for NeurodegenerationChapter 5 Aptamer and mRNA Platforms for Receptor Targeting and Protein ReplacementChapter 6 Genome Editing and Next-Generation Nucleic-Acid ToolsChapter 7 Precision Medicine and Nucleic Acid Therapies for Neurodegenerative DisordersChapter8 Challenges in the Development and Application of Nucleic Acid Therapies forNeurodegenerative DisordersChapter 9 Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative DisordersChapter 10 AI and Nucleic Acid Therapeutics in Neurodegenerative DiseaseChapter 11 Clinical Trials of Nucleic Acid Therapies for Neurodegenerative DisordersChapter 12 Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative DisordersChapter 13 Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative DisordersIndex

Dr. Trideva Sastri Koduru is a faculty member in pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA–based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR’s Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri’s research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.

• ForewordPrefaceAcknowledgmentsAbout the AuthorChapter 1 Introduction to Neurodegenerative DisordersChapter 2 Traditional Therapies for Neurodegenerative DiseasesChapter 3 Nucleic Acid Therapies for Neurodegenerative DisordersChapter 4 Antisense and RNA–Interference Strategies for NeurodegenerationChapter 5 Aptamer and mRNA Platforms for Receptor Targeting and Protein ReplacementChapter 6 Genome Editing and Next-Generation Nucleic-Acid ToolsChapter 7 Precision Medicine and Nucleic Acid Therapies for Neurodegenerative DisordersChapter8 Challenges in the Development and Application of Nucleic Acid Therapies forNeurodegenerative DisordersChapter 9 Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative DisordersChapter 10 AI and Nucleic Acid Therapeutics in Neurodegenerative DiseaseChapter 11 Clinical Trials of Nucleic Acid Therapies for Neurodegenerative DisordersChapter 12 Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative DisordersChapter 13 Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative DisordersIndex

Dr. Trideva Sastri Koduru is a faculty member in pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA–based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR’s Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri’s research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.

• ForewordPrefaceAcknowledgmentsAbout the AuthorChapter 1 Introduction to Neurodegenerative DisordersChapter 2 Traditional Therapies for Neurodegenerative DiseasesChapter 3 Nucleic Acid Therapies for Neurodegenerative DisordersChapter 4 Antisense and RNA–Interference Strategies for NeurodegenerationChapter 5 Aptamer and mRNA Platforms for Receptor Targeting and Protein ReplacementChapter 6 Genome Editing and Next-Generation Nucleic-Acid ToolsChapter 7 Precision Medicine and Nucleic Acid Therapies for Neurodegenerative DisordersChapter8 Challenges in the Development and Application of Nucleic Acid Therapies forNeurodegenerative DisordersChapter 9 Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative DisordersChapter 10 AI and Nucleic Acid Therapeutics in Neurodegenerative DiseaseChapter 11 Clinical Trials of Nucleic Acid Therapies for Neurodegenerative DisordersChapter 12 Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative DisordersChapter 13 Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative DisordersIndex